贝伐珠单抗联合TP方案的新辅助化疗对晚期卵巢癌患者的临床效果分析

Clinical Effect Analysis of Neoadjuvant Chemotherapy of Bevacizumab Combined with TP Regimen in Patients with Advanced Ovarian Cancer

摘要: 目的：探讨贝伐珠单抗联合TP方案新辅助化疗治疗晚期卵巢癌的临床效果，为临床用药提供参考。方法：回顾性分析2019年5月~2023年3月青岛大学附属医院妇科收治的60例晚期卵巢癌患者为研究对象，对照组患者接受紫杉醇 卡铂方案化疗，试验组患者在对照组的基础上联合贝伐珠单抗治疗。比较两组患者的临床疗效、临床相关指标和不良反应发生情况。结果：试验组治疗完整减瘤率为87.5%，优于对照组的50%，差异具有统计学意义(P < 0.05)。两组患者治疗后的临床相关指标比较，试验组的CA125、HE4、CA199均低于对照组，差异均有统计学意义(P < 0.05)。治疗前两组肿瘤直径比较，差异无统计学意义(P > 0.05)。治疗后，两组肿瘤直径与治疗前比较缩小，且试验组比对照组缩小明显，差异均有统计学意义(均P < 0.05)。而两组患者的不良事件发生率比较，差异无统计学意义(P > 0.05)。结论：贝伐珠单抗联合TP方案的新辅助化疗治疗晚期卵巢癌可提高手术的完整减瘤率，改善临床相关指标水平，且不增加不良事件发生率。

Abstract: Objective: To investigate the clinical effect of neoadjuvant chemotherapy of bevacizumab combined with TP regimen in the treatment of advanced ovarian cancer, and to provide reference for clinical use. Methods: A retrospective analysis of 60 patients with advanced ovarian cancer admitted to the Department of Gynecology, Affiliated Hospital of Qingdao University from May 2019 to March 2023 was conducted. The control group received chemotherapy with paclitaxel carboplatin, and the experimental group received combined treatment with bevacizumab on the basis of the control group. The clinical efficacy, clinical indicators and the occurrence of adverse reactions were compared between the two groups. Results: The complete tumor reduction rate of the experimental group was 87.5%, which was better than 50% of the control group, and the difference was statistically significant (P < 0.05). After treatment, the clinical indicators of CA125, HE4 and CA199 in the experimental group were lower than those in the control group, and the differences were statistically significant (P < 0.05). There was no significant difference in tumor diameter between the two groups before treatment (P > 0.05). After treatment, the tumor diameter of the two groups was smaller than that before treatment, and the study group was significantly smaller than the control group, with statistical significance (all P < 0.05). There was no significant difference in the incidence of adverse events between the two groups (P > 0.05). Conclusion: The neoadjuvant chemotherapy combined with bevacizumab and TP regimen in the treatment of advanced ovarian cancer can improve the complete tumor reduction rate, improve the level of clinical indicators, and do not increase the incidence of adverse events.